# SCYNEXIS, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SCYNEXIS, Inc). ## Overview SCYNEXIS, Inc. is a U.S.-based biopharmaceutical company focused on developing antifungal medicines for serious and drug-resistant fungal infections. Its core platform, called fungerps, includes ibrexafungerp and the follow-on candidate SCY-247, with development, licensing, and commercialization activities centered on human health applications. ## Products & services • Ibrexafungerp / BREXAFEMME for vulvovaginal candidiasis • SCY-247 oral and intravenous antifungal candidate • Proprietary fungerp antifungal platform • Licensing and collaboration rights for human-health antifungals - **Approved antifungal product** (5%) — Commercialized ibrexafungerp-based therapy marketed as BREXAFEMME for vaginal fungal infections. - **Clinical-stage antifungal candidates** (55%) — SCY-247 and other pipeline compounds being developed for difficult-to-treat fungal infections. - **License and royalty revenue** (40%) — Revenue from licensing arrangements and milestone/royalty economics tied to partnered assets. - Ibrexafungerp / BREXAFEMME for vulvovaginal candidiasis - SCY-247 oral and intravenous antifungal candidate - Proprietary fungerp antifungal platform - Licensing and collaboration rights for human-health antifungals ## Customers SCYNEXIS sells into the human-health pharmaceutical market rather than to end consumers directly, so its customers include licensing partners, healthcare providers, and ultimately patients treated with antifungal therapies. Commercial demand is tied to hospitals, clinicians, and payors that need treatments for fungal infections, especially where resistance or limited options make standard therapies less effective. - **Licensing partners** (primary) — Pharmaceutical companies such as GSK and other collaborators that pay for rights, milestones, and royalties. - **Healthcare providers** (primary) — Hospitals, specialists, and prescribers that use antifungal therapies in clinical settings. - **Patients with fungal infections** (primary) — Patients treated for vulvovaginal candidiasis, recurrent infections, or severe systemic fungal disease. - **Third-party payors** (secondary) — Commercial insurers and government programs that determine coverage and reimbursement. - Pharmaceutical partners that license development and commercialization rights - Hospitals and clinicians treating invasive or recurrent fungal infections - Patients with vulvovaginal candidiasis and other fungal diseases - Third-party payors that influence access and reimbursement - Researchers and development partners supporting pipeline advancement ## Geography SCYNEXIS is headquartered in the United States and conducts its core research, development, and corporate activities from there. Its business also extends through licensing arrangements outside the U.S., including partnered rights in China, Russia, and other non-core markets, which makes the company dependent on international regulatory and commercial execution. - United States is the main operating base for R&D and corporate functions - GSK Territory drives partnered commercialization outside the core U.S. setup - China rights are licensed through Hansoh for ibrexafungerp - Russia and several non-core markets are licensed to R-Pharm - International partners create royalty exposure across multiple jurisdictions ## Strategy SCYNEXIS is focused on advancing SCY-247 through clinical development while using its partnered assets to generate non-dilutive funding. The company also seeks to expand its pipeline through in-licensing and collaboration opportunities, which can broaden its antifungal franchise without relying solely on internal discovery. - **Complete SCY-247 clinical development milestones** (short-term) — Clinical progress is the main driver of future value creation for the pipeline. - **Monetize partnered assets through royalties and milestones** (short-term) — Partner economics can fund operations without relying entirely on new equity. - **Expand the antifungal portfolio through in-licensing** (medium-term) — Additional assets can diversify scientific risk and create future commercialization options. - Advance SCY-247 through Phase 1 and Phase 2 development - Use licensing and royalties to support development funding - Pursue non-dilutive capital to reduce reliance on equity - Evaluate in-licensing to expand the antifungal pipeline - Leverage proprietary fungerp science and regulatory designations ## Risks SCYNEXIS faces the typical risks of a development-stage biopharmaceutical company: clinical failure, regulatory delay, manufacturing dependence, and reimbursement uncertainty. Its partnered model also creates concentration risk around a small number of licensing relationships, while antifungal commercialization depends on competition from generic and established therapies. - **Clinical development failure for SCY-247** [high] — The lead pipeline asset is still in development and may not show adequate safety or efficacy. - **Regulatory approval and timing risk** [high] — Drug candidates require successful FDA and other regulatory reviews before commercialization. - **Manufacturing and supply chain dependence** [high] — The company relies on third-party CMOs and suppliers for drug product and clinical supply. - **Reimbursement and market access pressure** [medium] — Coverage decisions by payors can determine whether branded antifungals gain adoption. - **Competition from generic and established antifungals** [medium] — Existing therapies are widely available and may be cheaper or more familiar to prescribers. - Clinical trials may fail or produce insufficient efficacy or safety data - Regulatory approval could be delayed or denied for SCY-247 - Third-party manufacturing and CRO dependence can disrupt supply or trials - Reimbursement and formulary access may limit uptake of approved products - Competition from generic antifungals can pressure market adoption ## Accounting A key accounting issue is license agreement revenue, which depends on the timing and terms of collaboration milestones, royalties, and any cumulative catch-up adjustments. The company also has judgment-heavy estimates around clinical and manufacturing costs, stock-based compensation, and contingent obligations tied to partnerships and litigation. - **License agreement revenue recognition** — Can cause lumpy quarterly revenue and affect comparability - **Research and development expense estimation** — Affects reported operating loss and period timing - **Stock-based compensation** — Impacts SG&A and R&D expense trends - **Contingencies and litigation** — Could affect liabilities and future cash outflows - License revenue timing depends on collaboration milestones and contract terms - Royalty and milestone accounting can create period-to-period volatility - Clinical and CMC spending affects R&D expense recognition - Stock-based compensation and employee counts affect operating expense - Contingent liabilities and legal claims may require disclosure or accrual --- *Last updated: 2026-04-29T04:54:46.664378+00:00*